Ovarian Carcinoma: Signal Pathways and Clinical Studies
- 1Department of Gynecology and Obstetrics Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) Ministry of Education West China Second Hospital Sichuan University Chengdu People's Republic of China
Abstract
Ovarian carcinoma is the most lethal gynecologic malignancy, with a 5‐year survival rate for advanced patients that has remained stubbornly low due to high recurrence and acquired drug resistance. Despite advances in surgery and chemotherapy, a critical gap remains in translating an understanding of the tumor's complex molecular heterogeneity into effective, durable treatments. This review systematically dissects the latest advances in key signaling pathways driving ovarian carcinoma pathogenesis, including the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways, and critically evaluates the clinical progress of corresponding targeted therapies. We particularly focus on the regulatory networks within the tumor microenvironment and the mechanisms of crosstalk between pathways that contribute to treatment resistance. The review synthesizes clinical study outcomes for novel agents such as PARP inhibitors (olaparib and niraparib), antibody‐drug conjugates (e.g., T‐DXd), and anti‐angiogenic therapies (bevacizumab), while analyzing the challenges of primary and acquired resistance. By bridging fundamental pathway biology with emerging clinical data, this review provides a strategic framework for advancing precision medicine and developing rational combination therapies to improve outcomes for patients with this devastating disease.
Related
- Recent Developments in Studies on the Relation Between Endometriosis and Ovarian Cancer: Phenotype-Specific Risk, Molecular Convergence and Clinical Risk Stratification.
- Novel Replication Stress-Associated High-Grade Serous Ovarian Cancer Models Recapitulate Diverse Tumour Ecosystems and Enable Preclinical Studies
- Phenotypic Landscape of Programmed Death and TIGIT/CD155/DNAM-1 Pathways in NK Cells in Ovarian Cancer
- A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a BRCA1 pathogenic variant carrier
- Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study
BibTeX
@article{long2026ovarian,
title = {{Ovarian Carcinoma: Signal Pathways and Clinical Studies}},
author = {Yanru Long and Houhui Shi and Jiatian Ye and Xiaorong Qi},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.70975},
url = {https://doi.org/10.1002/mco2.70975},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ovarian Carcinoma: Signal Pathways and Clinical Studies
AU - Yanru Long
AU - Houhui Shi
AU - Jiatian Ye
AU - Xiaorong Qi
PY - 2026
DA - 2026/11/03
JO - MedComm
DO - 10.1002/mco2.70975
UR - https://doi.org/10.1002/mco2.70975
AB - Ovarian carcinoma is the most lethal gynecologic malignancy, with a 5‐year survival rate for advanced patients that has remained stubbornly low due to high recurrence and acquired drug resistance. Despite advances in surgery and chemotherapy, a critical gap remains in translating an understanding of the tumor's complex molecular heterogeneity into effective, durable treatments. This review systematically dissects the latest advances in key signaling pathways driving ovarian carcinoma pathogenesis, including the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways, and critically evaluates the clinical progress of corresponding targeted therapies. We particularly focus on the regulatory networks within the tumor microenvironment and the mechanisms of crosstalk between pathways that contribute to treatment resistance. The review synthesizes clinical study outcomes for novel agents such as PARP inhibitors (olaparib and niraparib), antibody‐drug conjugates (e.g., T‐DXd), and anti‐angiogenic therapies (bevacizumab), while analyzing the challenges of primary and acquired resistance. By bridging fundamental pathway biology with emerging clinical data, this review provides a strategic framework for advancing precision medicine and developing rational combination therapies to improve outcomes for patients with this devastating disease.
SN - 2688-2663
ER -